A Phase 2 clinical trial will test the safety and efficacy of an experimental treatment for dengue, a viral disease transmitted by mosquitoes.

The National Biocontainment Laboratories (NBLs) and Regional Biocontainment Laboratories (RBLs) provide BSL4/3/2 and BSL3/2 biocontainment facilities, respectively, for research on biodefense and emerging infectious disease agents.  

NIAID’s Diagnostics Development Services program offers reagents, platform testing, and planning and design support to accelerate product development of in vitro diagnostics (IVD) for infectious diseases, from research feasibility through clinical validation.

The Systems Biology Consortium for Infectious Diseases is a community of systems biologists who integrate experimental biology, computational tools and modeling across temporal and spatial scales to improve our understanding of infectious diseases. Through collaborative efforts, scientists test and validate hypotheses that drive innovation and discovery. The Consortium seeks to develop strategies that predict and alleviate disease severity and ultimately provide solutions to the world's most important health challenges.

The Therapeutic Development Services program offers a collection of preclinical services to support the development of products intended for use in the cure, mitigation, diagnosis, or treatment of disease caused by a pathogen or certain toxins.

This is one of several programs provided by NIAID's Division of Microbiology and Infectious Diseases to support infectious disease product developers.

The Vaccine and Treatment Evaluation Units (VTEUs), supported by the Division of Microbiology and Infectious Diseases (DMID) since the 1960s, provide a ready resource for the conduct of clinical trials to evaluate promising vaccines, treatments, and diagnostics for infectious diseases. The sites are part of DMID's Infectious Diseases Clinical Research Consortium (IDCRC).

The WRCEVA program maintains the Emerging Viruses and Arboviruses Reference Collection and provides reagents and support for investigations of virus outbreaks throughout the world. 

The Vaccine Development Services program offers a collection of preclinical services to support the development of vaccines intended for use in the investigation, control, prevention, and treatment of a wide range of infectious agents (other than HIV).

This is one of several programs provided by NIAID's Division of Microbiology and Infectious Diseases to support infectious disease product developers.

The Schistosomiasis Resource Center (SRC) provides three major strains of snails (Biomphalaria glabrata, Bulinus truncatus, and Oncomelania hupensis) and rodents infected with S. haematobium, S. japonicum, and S.mansoni. Molecular reagents include nucleic acids and genomic libraries from the various life cycle stages of the Schistosoma species (cercariae, schistosomula, adult worms and eggs).

Therapeutic Development Services - Interventional Agents program provides services to facilitate preclinical development of therapeutics and new in vivo diagnostics for infectious pathogens, including bacteria, viruses, parasites, fungi, and toxins. Services will be conducted at the appropriate regulatory compliance level dependent on the stage of product development.

Note: Devices are excluded.